Itulazax

Betula Verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual preparation for sublingual use. It is employed in allergy immunotherapy to induce tolerance to birch pollen allergens in patients with seasonal allergic conditions.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches for global distribution.

Itulazax is used in allergy immunotherapy targeting birch pollen–related allergic diseases.

- Birch pollen allergic rhinitis: reduces nasal congestion, sneezing and itching. - Birch pollen allergic conjunctivitis: alleviates eye redness, tearing and itching. - Birch pollen‑induced asthma: helps lower bronchial hyper‑responsiveness and medication need.

Sublingual administration of Itulazax may be associated with a range of adverse reactions.

Common Side Effects: - Oral itching or tingling: mild discomfort on the tongue or palate. - Throat irritation: transient soreness or scratchy sensation. - Mild gastrointestinal upset: occasional nausea or abdominal discomfort. - Local swelling: slight enlargement of the lips or mouth.

Serious or Rare Side Effects: - Anaphylaxis: rapid onset of systemic allergic reaction requiring emergency care. - Angioedema: swelling of face, lips, or airway that can compromise breathing. - Severe respiratory distress: wheezing or bronchospasm not relieved by usual rescue medication.

Before prescribing Itulazax, clinicians should evaluate patient suitability and monitor for reactions.

- Confirm diagnosis: verify birch pollen sensitization with skin testing or specific IgE. - Initiate under supervision: first dose administered in a medical setting. - Observe post‑dose: monitor patient for at least 30 minutes after initial administration. - Avoid in uncontrolled asthma: severe airway disease may increase risk of systemic reactions. - Contraindicated in severe immunodeficiency: patients with compromised immune systems should not receive. - Store at room temperature: keep in the original pack, protect from moisture and light.

Potential drug interactions should be reviewed before starting therapy.

Major Interactions (Avoid): - Beta‑blockers: may mask symptoms of anaphylaxis and complicate emergency treatment. - ACE inhibitors: can increase the risk of angioedema when combined with allergen exposure.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce the immunogenic response and affect efficacy. - Systemic corticosteroids: can interfere with the intended immune tolerance development. - Concurrent allergen extracts: simultaneous use may raise cumulative allergen load and heighten reaction risk.